Systematic Evaluation on Shengmai Injection in Treatment of Angina Pectoris in Coronary Heart Disease

WU Jia-rui; YANG Shu-yi; ZHANG Xiao-meng; ZHANG Dan; LIU Shi; ZHANG Bing; YANG Bing

doi:10.13422/j.cnki.syfjx.2015220222

您当前的位置：

首页 >

文章列表页 >

Systematic Evaluation on Shengmai Injection in Treatment of Angina Pectoris in Coronary Heart Disease

更新时间：2024-01-04

- Systematic Evaluation on Shengmai Injection in Treatment of Angina Pectoris in Coronary Heart Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 22, Pages: 222-225(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015220222
  CLC： R259
- Published：2015
- 稿件说明：
移动端阅览
WU Jia-rui, YANG Shu-yi, ZHANG Xiao-meng, et al. Systematic Evaluation on Shengmai Injection in Treatment of Angina Pectoris in Coronary Heart Disease[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(22): 222-225.
DOI：

WU Jia-rui, YANG Shu-yi, ZHANG Xiao-meng, et al. Systematic Evaluation on Shengmai Injection in Treatment of Angina Pectoris in Coronary Heart Disease[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(22): 222-225. DOI： 10.13422/j.cnki.syfjx.2015220222.

摘要

目的:系统评价生脉注射液治疗冠心病心绞痛的有效性及安全性。方法:计算机检索中国期刊全文数据库CNKI

万方数据库

维普数据库VIP

PubMed和Cochrane Library等数据库

全面收集生脉注射液治疗冠心病心绞痛的随机对照试验(RCT)的文献。采用Cochrane风险评价表进行文献质量评价

运用Revman 5.2软件进行Meta分析。结果:共纳入14项随机对照试验

共包括932例患者

其中实验组472例

对照组460例。Meta分析结果显示

在西医常规治疗的基础上

生脉注射液治疗冠心病心绞痛的临床疗效总有效率高于对照组

组间差异有统计学意义[RR=1.24

95%CI(1.17

1.32)

P<0.00001];在西医常规治疗的基础上

联合使用生脉注射液可以有效降低高敏C反应蛋白水平

差异具有统计学意义[MD=-4.46

95%CI(-6.79

-2.12)

P=0.0002];在西医常规治疗的基础上

联合使用生脉注射液可以有效降低血浆黏度

差异具有统计学意义[MD=-0.11

95%CI(-0.18

-0.03)

P=0.006]。结论:生脉注射液用于治疗冠心病心绞痛具有较好疗效。

Abstract

Objective: To systematically evaluate the clinical efficacy and safety of Shengmai injection in the treatment of angina pectoris in coronary heart disease. Method: Literatures concerning randomized controlled trials(RCTs) regarding Shengmai injection in the treatment of angina pectoris in coronary heart disease were searched in CNKI

VIP

WanFang Database

CBM

PubMed

Embase and Cochrane Library. Quality of the included studies was evaluated with the method recommended in Cochrane

extracted the required information

and statistical was performed using the Review Manager 5.2 software. Result: A total of 14 RCTs with 932 participants were included

and the experimental group was 472 cases and the control group was 460 cases. Clinical effect analysis:Firstly

9 studies included compare the total clinical effective rate

the Meta-analysis indicated that Shengmai injection combined with conventional treatment with western medicine is effective in treating angina pectoris in coronary heart disease

on the basis of conventional therapy

Shengmai injection's total clinical effective rate is higher compared to the control group

there were statistically significant differences between groups[RR=1.24

95%CI(1.17

1.32)

P<0.00001]. Secondly

3 studies compared Hs-CRP and the Meta-analysis indicated that Shengmai injection combined with conventional treatment with western medicine can reduce Hs-CRP effectively[MD=-4.46

95%CI(-6.79

-2.12)

P=0.0002]. Finally

2 studies compared the rheology of blood and the Meta-analysis indicated Shengmai injection combined with conventional treatment with western medicine can reduce rheology of blood effectively[MD=-0.11

95%CI(-0.18

-0.03)

P=0.006]. Conclusion: Shengmai injection combined with conventional treatment with western medicine is effective in treating cardiovascular and cerebrovascular diseases.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Shengmai Injection Against Cerebral Ischemia Based on Proteomics

Medication Rules and Academic Experience of Professor WANG Xingkuan in Treatment of Chest Stuffiness and Pain Based on Data Mining

Analysis of Modular Network Mechanism of Danhong Injection in Treatment of Coronary Angina Pectoris

Influence of Injection on the Tissue Concentration of Digoxin in Rats with Heart Failure

Main Active Section on Human Umbilical Vein Endothelial Cells Hypoxia/reoxygenation Injury Model in Shengmai Injection

Related Author

WU Hongwei

LIU Jingtong

HU Shaowei

CHANG Mengli

XU Jing

CAI Qingqing

LI Xinghong

TANG Liying

Related Institution

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

School of Pharmacy，Zunyi Medical University

Hospital of Integrated Chinese and Western Medicine

Hunan University of Chinese Medicine

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰